Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Serotonin Syndrome 1Neuroendocrine Tumors 1Carcinoid Tumors, Intestinal 1Carcinoid Tumor 1

Interventions

pembrolizumab 290Carboplatin 219Gemcitabine 150Cisplatin 150Paclitaxel 149Pemetrexed 119Bevacizumab 117Docetaxel 101Oxaliplatin 83durvalumab 80Fluorouracil 80Nivolumab 77Dexamethasone 77Cyclophosphamide 76atezolizumab 73130-nm albumin-bound paclitaxel 71Fulvestrant 69Capecitabine 69Injections 64Leucovorin 63Cetuximab 58Rituximab 56Lenalidomide 52fludarabine 50venetoclax 45Prednisone 44Irinotecan 42Letrozole 40ribociclib 38tislelizumab 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Random Allocation × 90 days × Clear all
NCT05361668 2026-03-19

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Crinetics Pharmaceuticals Inc.

Phase 2 Completed
36 enrolled 19 charts
EndocrineNET

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡